Abbott

Abbott, a US-based Electromedical and Electrotherapeutic Apparatus Manufacturing company, reported its most recent emissions data for 2024. The total market-based emissions for 2024 were approximately 9.35 billion kg CO2e. This includes Scope 1 emissions of 502 million kg CO2e, Scope 2 market-based emissions of 393 million kg CO2e, and Scope 3 emissions of approximately 8.45 billion kg CO2e. Key categories within Scope 3 include purchased goods and services (7.06 billion kg CO2e) and upstream transportation and distribution (1.24 billion kg CO2e).

Abbott has set several climate commitments and reduction targets. The company aims to reduce its absolute Scope 1 and 2 GHG emissions by 30% by 2030, using a 2018 baseline. This target aligns with the Science Based Targets initiative (SBTi) and is consistent with reductions required to keep warming to well below 2°C. Additionally, Abbott commits that 82% of its suppliers, by emissions covering purchased goods and services and upstream transportation and distribution, will have science-based targets by 2026. A UK subsidiary, Abbott Laboratories Ltd., has committed to achieving Net Zero emissions by 2050.